Lilly’s triple-hormone drug produced some of the largest weight loss ever seen in obesity trials. It isn’t approved yet — and a fast-growing online market selling it as a “research peptide” carries real dangers.
A University of Florida study of health records found people with memory problems who took glucosamine were more likely to progress to dementia. It is an association, not proof — but mouse experiments point to a plausible mechanism.
CRISPR Therapeutics’ CTX310 switches off the ANGPTL3 gene in the liver. One-year follow-up in a small first-in-human trial shows LDL and triglycerides stayed down with no serious treatment-related side effects.
Efsitora alfa turns 365 basal insulin injections a year into 52. It is the second weekly insulin cleared in the US this year — and a sign that diabetes care is shifting toward fewer, longer-acting doses.
Two Mount Sinai studies show how APOE4 turns key blood-vessel support cells into scar-forming cells, and that blocking one signal restored vessels in aged mice. It is early science with a clear lead.
Both promise to spot signs of dozens of cancers from a single blood draw, and neither is FDA-approved yet. Here is how they differ on what they measure, how often they raise false alarms, what happens after a positive result, and cost.
Both are once-daily GLP-1 tablets for weight loss, and both start at $149 a month. But they are very different drugs — and the differences in how you take them, how much weight people lost, and what higher doses cost are worth knowing.
Sefaxersen significantly cut a key marker of kidney damage in a rare disease that has suddenly attracted a wave of new treatments — and Roche is betting a once-monthly, at-home injection can stand out.
A plain-language guide to Berger’s disease — what goes wrong in the kidneys, how it is found, why it is more serious than once thought, and how a wave of new drugs has changed treatment.
An FDA advisory panel voted that the benefits of Grail’s Galleri outweigh its risks — but a split vote on effectiveness, and a missed goal in a major UK trial, show how much is still unsettled.
A quiet FDA rule change — letting bone-density scans stand in for fractures in trials — is reigniting drugmaker and investor interest in a common disease that had fallen out of fashion.
In a rare joint letter, the chairs of Europe’s biggest drugmakers say the continent’s share of pharmaceutical research and investment is sliding — and urge governments to act before the decline becomes permanent.